Jnpmedi

Jnpmedi is a South Korean healthcare IT company founded in 2020 by CEO Kwunho Jeong (also cited as Jeong Kwun-ho and Jeon Jeong-ho). The company provides a cloud-based data platform, Maven Clinical Cloud, to digitize and streamline clinical research and trial operations. Its solutions cater to pharmaceutical companies, biotech firms, medical device manufacturers, and clinical research organizations.

The company's core offering, Maven Clinical Cloud, is an end-to-end eClinical solution that manages the entire clinical trial lifecycle, from protocol design to data collection, monitoring, and analysis. This platform utilizes technologies like blockchain and cloud computing to ensure data integrity and security. The suite includes various modules such as Maven CDMS for data management, Maven eCOA for patient data collection, Maven eRecruitment for online subject recruitment, and Maven eConsent for electronic consent collection. In 2024, the company expanded its offerings to include professional services, covering business strategy, product development, regulatory strategy, and licensing.

Jnpmedi operates on a subscription-based business model with different tiers for its services. The company has successfully raised capital to fund its growth and global expansion. In December 2021, it secured an undisclosed seed amount. This was followed by a Series A funding round in November 2022, where it raised 14 billion won (approximately $10.3 million), led by Pavilion Capital, a subsidiary of Singapore's Temasek, with participation from Kakao Ventures, Murex Partners, AJU IB Investment, and Gentium Partners.

Keywords: clinical trial software, eClinical solutions, decentralized clinical trials, clinical data management, healthcare IT, pharmaceutical research, medical data platform, Life Science RDC, Maven Clinical Cloud, digital therapeutics, CRO services, blockchain in healthcare, cloud clinical trials, regulatory compliance, HealthTech, medical software, data integrity, patient recruitment, eConsent, eCOA